Company: GIFLF
Filing Date: 2025-02-26
Form Type: 6-K
Source: 0001104659-25-017501
Chunk: 19

Company: Grifols SA
Filing Date: 2025-02-26
Form: 6-K
Chunk 19
---
 currency (cc) excludes exchange rate fluctuations over the period. Grifols Grifols % vs PY

- 29 - Q4 2024 Results Revenue | 2024 Introductory Remarks Business Performance Financials Final remarks Annex FY 2024 FY 2023 In thousands of euros Reported At cc* Revenue by Business Unit 7,212,382 6,591,977 9.4% 10.3% Biopharma 6,142,588 5,558,301 10.5% 11.3% Diagnostic 644,898 670,269 (3.8%) (2.1%) Bio Supplies 215,664 159,957 34.8% 35.3% Others & intersegments 209,232 203,450 2.8% 3.5% Revenue by Country 7,212,382 6,591,977 9.4% 10.3% US + CANADA 4,087,030 3,898,961 4.8% 5.6% EU 1,498,898 1,255,927 19.3% 19.4% ROW 1,626,455 1,437,089 13.2% 15.1% * Constant currency (cc) excludes exchange rate fluctuations over the period. Grifols Grifols % vs PY

- 30 - Q4 2024 Results P&L | Q4 2024 Introductory Remarks Business Performance Financials Final remarks Annex In thousands of euros Reported One-offs Reported excl. One-offs Reported One-offs Reported excl. One-offs Reported Reported excl. One-offs Net Revenue 1,975,813 - 1,975,813 1,769,551 - 1,769,551 11.7% 11.7% Cost of Sales (1,209,319) 10,118 (1,199,201) (1,077,832) 37,538 (1,040,294) (12.2%) (15.3%) Gross Margin 766,494 10,118 776,612 691,719 37,538 729,257 10.8% 6.5% % Net revenue 38.8% - 39.3% 39.1% - 41.2% - - R&D (115,001) 18,572